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Abstract
Background: Amplified MYCN oncogene resulting in deregulated MYCN transcriptional activity is observed in 20%
of neuroblastomas and identifies a highly aggressive subtype. In MYCN single-copy neuroblastomas, elevated MYCN
mRNA and protein levels are paradoxically associated with a more favorable clinical phenotype, including
disseminated tumors that subsequently regress spontaneously (stage 4s-non-amplified). In this study, we asked
whether distinct transcriptional MYCN or c-MYC activities are associated with specific neuroblastoma phenotypes.
Results: We defined a core set of direct MYCN/c-MYC target genes by applying gene expression profiling and
chromatin immunoprecipitation (ChIP, ChIP-chip) in neuroblastoma cells that allow conditional regulation of MYCN
and c-MYC. Their transcript levels were analyzed in 251 primary neuroblastomas. Compared to localized-non-
amplified neuroblastomas, MYCN/c-MYC target gene expression gradually increases from stage 4s-non-amplified
through stage 4-non-amplified to MYCN amplified tumors. This was associated with MYCN activation in stage 4s-
non-amplified and predominantly c-MYC activation in stage 4-non-amplified tumors. A defined set of MYCN/c-MYC
target genes was induced in stage 4-non-amplified but not in stage 4s-non-amplified neuroblastomas. In line with this,
high expression of a subset of MYCN/c-MYC target genes identifies a patient subtype with poor overall survival
independent of the established risk markers amplified MYCN, disease stage, and age at diagnosis.
Conclusions: High MYCN/c-MYC target gene expression is a hallmark of malignant neuroblastoma progression,
which is predominantly driven by c-MYC in stage 4-non-amplified tumors. In contrast, moderate MYCN function
gain in stage 4s-non-amplified tumors induces only a restricted set of target genes that is still compatible with
spontaneous regression.
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Neuroblastoma is the most common extracranial malignant
solid tumor in early childhood. Clinical courses are highly
variable, ranging from spontaneous regression to therapy-
resistant progression. Clinical and biological features, such as
age at diagnosis, disease stage, numerical (ploidy) and struc-
tural chromosomal alterations (MYCN gene amplification;
1p, 3p, 11q deletions; 17q gain), are associated with patient
outcome [1,2]. Amplified MYCN oncogene identifies a sub-
type with poor prognosis [3] and is consistently associated
with high MYCN mRNA and protein levels. There is strong
experimental evidence (ectopic MYCN expression in cell
lines, N-myc transgenic neuroblastoma mouse model) that
increased MYCN activity is involved in tumor initiation and
progression of at least a subset of neuroblastomas [4,5].
The MYC gene family members, c-MYC, MYCN and MYCL,
are involved in the biology of many cancer types. They encode
basic helix-loop-helix leucine zipper proteins that are found
as heterodimers with their obligate partner protein, MAX [6].
The MYC-MAX heterodimer binds to DNA consensus core
binding sites, 5'-CACGTG-3' or variants thereof (E-boxes),
which preferentially leads to transcriptional activation of tar-
get genes. Repression of target genes by MYC proteins has
also been described [7]. This seems to be independent of the
binding of MYC proteins to E-boxes, but involves a cofactor,
Miz-1, that tethers MYC-MAX to gene promoters, such as p15
and p21. Enhanced activity of MYC transcription factors con-
tributes to almost every aspect of tumor formation: unre-
stricted cell proliferation, inhibition of differentiation, cell
growth, angiogenesis, reduced cell adhesion, metastasis, and
genomic instability [6,8]. In contrast, MYC transcription fac-
tors, including MYCN, also sensitize cells for apoptosis, a
function that should inhibit tumor formation and that could
also be involved in spontaneous tumor regression [9].
Spontaneous tumor regression does occur in neuroblastoma,
at a higher frequency than in any other cancer type. This proc-
ess resembles the physiological concurrence of massive cellu-
lar suicide (apoptosis) and differentiation of a few neurons
along the sympathoadrenal cell lineage in the normal devel-
opment of the sympathetic nervous system. Spontaneous
regression is most frequently observed in a subset of dissem-
inated MYCN single-copy neuroblastomas (non-amplified
(NA)), termed stage 4s (stage 4s-NA) [10]. However, popula-
tion-based screening studies for neuroblastomas in Japan,
Quebec and Germany suggest that spontaneous regression
also occurs in other neuroblastoma subtypes, predominantly
localized (stages 1, 2, 3) neuroblastomas (localized-NA) [11-
13]. Paradoxically, MYCN mRNA and protein levels are
higher in favorable localized-NA and, particularly, in stage
4s-NA tumors than in stage 4-NA tumors with poor outcome
[14-16], but they do not reach the levels observed in MYCN
amplified tumors. In line with this, neuroblastoma cells with
elevated MYCN expression retain their capacity to undergo
apoptosis [17] or neuronal differentiation [18]. Thus, it has
been speculated that MYCN does not only mediate malignant
progression in MYCN amplified tumors, but is also either
involved or at least compatible with spontaneous regression
in favorable neuroblastomas. In contrast, a functional role of
MYCN in stage 4-NA tumors with low MYCN levels is ques-
tionable. Here, other transcription factors or pathways within
or outside the MYC family of transcription factors could be
more relevant. Neuroblastoma-derived cell lines that lack
amplified MYCN generally express c-MYC rather than MYCN,
often at higher levels than normal tissues [19,20]. However,
transcriptional activity of MYCN or c-MYC as reflected by the
transcript levels of direct MYCN/c-MYC target genes in rela-
tion to MYCN and c-MYC levels has not yet been defined in
neuroblastoma subtypes.
Here, we defined a core set of MYCN and c-MYC target genes
by using oligonucleotide microarrays and a neuroblastoma
cell line that allows conditional expression of MYCN or c-
MYC. Direct regulation of these target genes by MYCN/c-
MYC was assessed by analyzing the binding of MYCN and c-
MYC protein to target gene promoters using PCR- and array-
based chromatin immunoprecipitation (ChIP and ChIP-chip,
respectively) in different neuroblastoma cell lines. We further
investigated the expression of these direct MYCN/c-MYC tar-
get genes in relation to MYCN and c-MYC expression in dif-
ferent clinical neuroblastoma subtypes. In addition, the
association of MYCN/c-MYC target gene expression with
overall survival independent of the well-established markers
- amplified MYCN, disease stage and age at diagnosis - was
demonstrated.
Results
Inverse correlation of MYCN and c-MYC expression in 
neuroblastoma subtypes
c-MYC mRNA levels are very low in MYCN amplified tumors
(Figure 1), which is due to high MYCN protein repressing c-
MYC mRNA expression [20]. Previous quantitative PCR anal-
yses in a cohort of 117 neuroblastoma patients revealed that
mRNA levels of MYCN are significantly lower in stage 4-NA
than in stage 4s-NA (p = 0.008) and localized-NA neuroblas-
tomas (stages 1, 2, 3; p = 0.03) [14]. To test whether this lower
expression of MYCN in stage 4-NA tumors is due to elevated
c-MYC activity that represses MYCN expression, we analyzed
c-MYC and MYCN mRNA levels in a cohort of 251 primary
neuroblastoma tumors using a customized 11K oligonucle-
otide microarray (other MYC gene family members were not
differently expressed (data not shown)). Although c-MYC
mRNA levels were not significantly higher in stage 4-NA (n =
52) than in localized-NA tumors (n = 138), we found an
inverse correlation of MYCN and c-MYC expression between
stage 4s-NA (n = 30) and stage 4-NA tumors. Stage 4-NA
tumors showed lower expression of MYCN and higher expres-
sion of c-MYC, whereas stage 4s-NA tumors showed lower
expression of c-MYC and higher expression of MYCN (Figure
1; p = 0.008 for c-MYC, p = 0.07 for MYCN).Genome Biology 2008, 9:R150
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Inverse correlation of MYCN and c-MYC mRNA levels in neuroblastoma subtypes. Relative mRNA expression is shown for MYCN and c-MYC as well as for 
MDM2, DKC1, and PTMA, three direct targets of MYCN/c-MYC. Data are represented as box plots: horizontal boundaries of boxes represent the 25th 
and 75th percentile. The 50th percentile (median) is denoted by a horizontal line in the box and whiskers above and below extend to the most extreme 
data point, which is no more than 1.5 times the interquartile range from the box. A set of 251 primary neuroblastoma tumors was analyzed consisting of 
138 localized-NA (stage 1/2/3), 30 stage 4s-NA, 52 stage 4-NA and 31 MYCN amplified (AMP) neuroblastoma tumors. Gene expression levels from stage 
4s-NA, stage 4-NA, and MYCN amplified tumors were compared pair-wise with those of localized-NA tumors as reference. Differential gene expression 
was assessed for each gene by using the Mann-Whitney test (cut-off of p < 0.05).
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in stage 4-NA tumors should both result in high expression of
shared target genes compared to localized-NA neuroblasto-
mas, we analyzed known direct MYCN/c-MYC target genes,
namely MDM2 [21], DKC1 [22], and PTMA [23], in neurob-
lastoma subtypes. As expected, the highest expression of all
three transcripts was observed in MYCN amplified tumors
(Figure 1; p < 0.001 for all three transcripts, n = 31). MDM2
mRNA levels were higher in stage 4-NA (p = 0.005) and stage
4s-NA (p = 0.03) than in localized-NA tumors (the expression
range of MDM2 is large because of two MYCN amplified
tumors with non-syntenic co-amplification of MDM2 (data
not shown)). Similarly, DKC1 and PTMA expression was
higher in stage 4-NA (p < 0.001 for DKC1, p = 0.02 for PTMA)
and in stage 4s-NA (p = 0.03 for DKC1, p = 0.007 for PTMA)
than in localized-NA tumors. These results suggest an
increased MYCN/c-MYC activity also in stage 4s-NA (MYCN)
and in stage 4-NA (predominantly c-MYC) compared to local-
ized-NA tumors. However, higher DKC1 mRNA levels in stage
4-NA tumors and higher PTMA mRNA levels in stage 4s-NA
tumors also suggest differential regulation of MYCN/c-MYC
target genes in these subtypes. To further analyze MYCN/c-
MYC activity as well as differential regulation of MYCN/c-
MYC target genes in neuroblastoma subtypes, we thought to
define a comprehensive set of target genes directly regulated
by MYCN and/or c-MYC in neuroblastoma cells.
Repression of endogenous c-MYC by targeted 
expression of a MYCN transgene in SH-EPMYCN cells 
defines c-MYC- and MYCN-regulated genes
To identify MYCN/c-MYC-regulated genes in neuroblastoma
cells, we employed the experimental system SH-EPMYCN,
which stably expresses a tetracycline-regulated MYCN trans-
gene [23]. Exponentially growing SH-EPMYCN cells cultured
with tetracycline express c-MYC but almost no MYCN protein
(Figure 2a). Induction of MYCN by removing tetracycline
from the medium is associated with a rapid reduction of c-
MYC at the mRNA and protein levels. c-MYC reduction
occurs prior to the full expression of ectopically induced
MYCN protein (Figure 2a). Accordingly, mRNA levels of
direct MYCN/c-MYC targets, such as PTMA and DKC1, ini-
tially decline before accumulating MYCN protein leads to the
re-induction of these genes. Similar profiles were observed
with direct MYCN target genes, such as MDM2 and MCM7
(Additional data file 1).
We used SH-EPMYCN cells for a global search of MYCN and c-
MYC target genes in neuroblastoma cells using a customized
neuroblastoma oligonucleotide microarray (11K, Agilent) that
was enriched with probes for genes differentially expressed in
neuroblastoma subtypes and for direct MYCN/c-MYC target
genes [14,24]. Gene expression profiles of SH-EPMYCN cells at
2, 4, 8, 12, 24, and 48 hours after targeted MYCN expression
were generated. Self-organizing maps (SOMs) were used to
capture the predominant pattern of gene expression. This
analysis yielded 504 clusters (best matching units (BMUs))
consisting, on average, of 20 clones per cluster (Additional
data file 1). We searched for clusters with characteristic gene
expression profiles of direct MYCN/c-MYC target genes. In
addition, known c-MYC target genes from a public database
[25] and known MYCN target genes from a literature search
were mapped to the 504 clusters (Additional data file 2). A
significant enrichment of known MYCN/c-MYC targets was
found in 6 clusters (clusters 140, 168, 195, 280, 308, and 336;
p < 0.05, adjusted for multiple testing), consisting of 167
genes. The genes in these six clusters were induced by MYCN
and c-MYC in SH-EPMYCN cells. Based on their average gene
expression profiles, we grouped the clusters into two sub-
groups, I and II. Subgroup I genes (clusters 140, 168, and 195)
were expressed at equal levels in SH-EPMYCN cells expressing
endogenous c-MYC (2 hours) and in those fully expressing
ectopic MYCN (24 and 48 hours), despite the fact that the
maximum protein level of MYCN was significantly higher
than that of endogenous c-MYC (Figure 2a; Additional data
file 1). This indicates that subgroup I genes are regulated by
MYCN, and also suggests that they are less responsive to
MYCN than to c-MYC in SH-EPMYCN cells. The mRNA levels
of subgroup II genes (clusters 280, 308, and 336) were high-
est in SH-EPMYCN cells fully expressing ectopic MYCN and fol-
lowed the combined absolute c-MYC and MYCN protein
levels during the time course experiment. We also found clus-
ters with MYCN and c-MYC repressed genes (for example,
subgroup III; Additional data file 1). However, enrichment of
known MYCN/c-MYC repressed genes from the literature/
database in defined clusters was not found using our statisti-
cal cut-off (after adjustment for multiple testing, no cluster
showed p < 0.05). This was at least partly due to the fact that
in SH-EPMYCN cells, some genes were repressed by MYCN but
not by c-MYC (subgroup IV). In addition, c-MYC repressed
genes from different experimental systems compiled in the c-
MYC target gene database were not necessarily repressed by
MYCN and/or c-MYC in SH-EPMYCN cells.
Therefore, we focused on genes for further validation that
were induced by both MYCN and c-MYC proteins in SH-
EPMYCN cells and grouped into subgroup I and II. We
extracted all available promoters from the genes represented
on the array and scanned for canonical E-boxes (CACGTG)
and for the 12 bp MYCN position-weight matrix [26] within 
-2 kb and +2 kb of the transcriptional start site. We ranked all
504 clusters according to the relative number of putative
MYCN/c-MYC binding sites in each cluster. All clusters from
subgroups I and II were among the 15 top-ranked clusters
with enrichment of predicted MYCN/c-MYC binding sites
(data not shown).
To further validate target gene regulation by MYCN/c-MYC in
neuroblastoma cells, we performed ChIP-chip using a 244K
oligonucleotide promoter microarray (Agilent). We analyzed
the binding of MYCN and c-MYC to the promoters of the 147
subgroup I and II genes that were represented on the 244K
promoter microarray. We used five neuroblastoma cell linesGenome Biology 2008, 9:R150
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Figure 2
Identification and validation of MYCN/c-MYC target genes in neuroblastoma cell lines. (a) Repression of endogenous c-MYC by targeted expression of a 
MYCN transgene in SH-EPMYCN cells defines MYCN/c-MYC-regulated genes. MYCN and c-MYC protein levels were monitored in a time series after 
removing tetracycline in exponentially growing SH-EPMYCN cells that stably express a tetracycline-regulated MYCN transgene. Mean and standard deviation 
of the relative mRNA levels of MYC, DKC1 and PTMA are given from two time series experiments as measured by a customized neuroblastoma oligo 
microarray. (b) Hierarchical clustering of MYCN- and c-MYC binding to 140 target gene promoters as measured by ChIP-chip in 6 neuroblastoma cell 
lines. ChIP-chip results of 140 MYCN/c-MYC target genes from 5 neuroblastoma cell lines that preferentially express either high levels of MYCN (SH-
EPMYCN, IMR5/75 (approximately 75 copies of MYCN) and Kelly (approximately 100-120 copies of MYCN)) or c-MYC (SJ-NB12 and SY5Y). Additionally, as 
an intermediate type, parental SH-EP cells were analyzed. SH-EP cells preferentially express c-MYC, but also low levels of MYCN. ChIP-chip experiments 
were performed with a monoclonal antibody against human MYCN and a polyclonal antibody against human c-MYC for each neuroblastoma cell line. A 
cut-off for positive binding was set for both transcription factors to >4-fold enrichment for one and >2-fold enrichment of at least one of the two 
neighboring probes. MYCN/c-MYC-binding is color-coded as follows: blue, c-MYC binding; red, MYCN/c-MYC binding; dark red, MYCN binding; light 
yellow, lack of MYCN/c-MYC binding. Hierarchical clustering was used to group neuroblastoma cell lines according to their MYCN/c-MYC-binding 
pattern. Differentiation between MYCN and c-MYC-binding was mainly achieved through the monoclonal MYCN antibody. The polyclonal antibody 
against c-MYC also gave positive binding signals for a large set of analyzed target gene promoters in neuroblastoma cell lines with high MYCN that lack c-
MYC expression (SH-EPMYCN, IMR5/75 and Kelly).
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EPMYCN, IMR5/75 (approximately 75 copies of MYCN), and
Kelly (approximately 100-120 copies of MYCN)) or c-MYC
(SJ-NB12 and SY5Y). Additionally, as an intermediate type,
parental SH-EP cells were analyzed, which preferentially
express c-MYC, but also MYCN at low level [20,23]. ChIP-
chip experiments were performed with a monoclonal anti-
body against human MYCN and a polyclonal antibody against
human c-MYC for each of the neuroblastoma cell lines. A cut-
off for positive binding was defined as >4-fold enrichment for
one probe together with >2-fold enrichment for at least one of
the two neighboring probes compared to input control. In
addition, we manually inspected each of the MYCN and c-
MYC-binding profiles from the 147 genes. Seven genes were
excluded from the analysis because the probe sets for the
genes mapped within the genes but outside the target gene
promoter regions (all profiles for Kelly and SJ-NB12 cell lines
are given in Additional data files 3 and 4, respectively; MYCN-
and c-MYC-binding results are given in Additional data files
5-7). We also performed PCR-based ChIP for selected candi-
date genes (n = 13; Additional data file 8), which all showed
analogous results to ChIP-chip (data not shown). Almost all
140 target gene promoters showed binding of MYCN and/or
c-MYC in the six analyzed neuroblastoma cell lines as meas-
ured by ChIP-chip (Figure 2b). Intriguingly, hierarchical clus-
tering of neuroblastoma cell lines according to the MYCN/c-
MYC-binding pattern clearly separated MYCN- and c-MYC-
expressing neuroblastoma cell lines. Differentiation between
MYCN and c-MYC binding was mainly achieved through the
monoclonal anti-MYCN antibody. The polyclonal antibody
against c-MYC also gave positive binding signals for a large
set of target gene promoters in neuroblastoma cell lines with
high MYCN that lack detectable c-MYC expression (SH-
EPMYCN, IMR5/75 and Kelly). This was most likely due to
unspecific binding of the polyclonal c-MYC antibody to
MYCN in these cells. Nevertheless, the lack of binding of
MYCN to a large set of target gene promoters in the c-MYC-
expressing cells, SJ-NB12 and SY5Y, and the positive binding
of c-MYC to almost all of these target gene promoters in these
cells allowed the distinction between MYCN and c-MYC.
Taken together, these results indicate that the genes from
subgroups I and II represent a core set of target genes directly
regulated by either MYCN or c-MYC in neuroblastoma cells
dependent on which MYC protein is expressed.
Gradual increase of MYCN/c-MYC target gene 
expression from stage 4s-NA through stage 4-NA to 
MYCN amplified tumors
To determine transcriptional activity of MYCN/c-MYC pro-
teins in primary neuroblastomas (n = 251), we analyzed dif-
ferential expression of subgroup I and II genes in
neuroblastoma subtypes using the Global test as proposed by
Goeman et al. [27]. Almost all these genes (154 of 167; 92%)
showed highest expression in MYCN amplified tumors, sug-
gesting that regulation of these genes by MYCN is similar in
neuroblastoma cell lines and tumors. Compared to localized-
NA tumors (stages 1, 2, 3), expression of subgroup I and II
genes was significantly associated with stage 4s-NA (p =
0.002), stage 4-NA (p < 0.001) and MYCN amplified tumors
(p < 0.001). Global test results further indicated that an
increasing number of MYCN/c-MYC target genes was
induced from stage 4s-NA through stage 4-NA to MYCN
amplified tumors (Additional data files 9-11). To further illus-
trate this, we grouped each of the 154 genes into one of four
classes based on pair-wise comparisons (Mann-Whitney test,
cut-off p < 0.05). These were, compared to localized-NA
tumors: overexpressed in MYCN amplified and in stage 4s-
NA tumors (class 1); overexpressed in MYCN amplified, stage
4-NA and stage 4s-NA tumors (class 2); overexpressed in
MYCN amplified tumors (class 3); overexpressed in MYCN
amplified and stage 4-NA tumors (class 4) (Figure 3). Com-
pared to localized-NA tumors, 25 (16%) of the 154 MYCN/c-
MYC target genes, including CCT4, FBL, MDM2, NCL, NPM1,
PTMA, and TP53, were expressed at higher levels in stage 4s-
NA tumors (Table 1). Eighty-eight (57%) of the 154 MYCN/c-
MYC target genes, including 21 of those overexpressed also in
stage 4s-NA tumors, were expressed at higher levels in stage
4-NA than in localized-NA tumors (Table 1, class 2; Addi-
tional data file 5). Accordingly, stage 4-NA tumors shared
overexpression of 68 of 154 direct MYCN/c-MYC target genes
(44%), including AHCY, RUVBL1, PHB, CDK4, and MRPL3,
with MYCN amplified tumors. Together, this indicates that
besides MYCN amplified tumors, stage 4-NA tumors, and to
a lesser extent stage 4s-NA tumors, also show higher MYCN/
c-MYC activity compared to localized-NA tumors. In line with
this, we also found lower mRNA levels of an increasing
number of MYCN/c-MYC repressed genes from stage 4s-NA
(10 out of 68 (15%) in vitro validated repressed genes that are
also lower in MYCN amplified tumors) through stage 4-NA
(34 out of 68 (50%)) to MYCN amplified tumors (68 out of
102 in vitro validated repressed genes had the lowest expres-
sion levels in MYCN amplified tumors (67%)). Based on the
relative expression of MYCN and c-MYC in neuroblastoma
subtypes, we propose that elevated MYCN activity in stage 4s-
NA tumors induces only a restricted set of MYCN/c-MYC tar-
get genes, whereas elevated c-MYC activity in stage 4-NA
tumors induces a larger set of MYCN/c-MYC target genes.
High expression of MYCN/c-MYC target genes is a 
robust marker of poor overall survival independent of 
genomic MYCN status, age at diagnosis and disease 
stage
Having shown that MYCN/c-MYC target gene activation is
also associated with distinct neuroblastoma subtypes, we
wanted to test whether MYCN/c-MYC activity as determined
by the expression levels of their target genes is associated with
overall survival and improves outcome prediction independ-
ent of known risk markers. We used the Global test to test the
influence of each of the 504 experimentally defined gene clus-
ters on overall survival directly, without the intermediary of
single gene testing. The p-values for each cluster were
adjusted for multiple testing and ranked according to theirGenome Biology 2008, 9:R150
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with overall survival of the six MYCN/c-MYC target gene clus-
ters and the rank in relation to all other clusters. In a separate
analysis, we determined the association with overall survival
for each of the 504 experimental gene clusters adjusted for
amplified MYCN, stage 4 versus stages 1, 2, 3, and 4s, and age
at diagnosis ≥1.5 years (Table 2). These well-established risk
markers highly correlated with poor outcome in univariate
analyses (p < 0.001 for each of these three markers). As
expected, the Global test without adjustment for co-variables
indicated that all MYCN/c-MYC target gene clusters were sig-
nificantly associated with poor overall survival (p < 0.001).
Intriguingly, all six MYCN/c-MYC target gene clusters
remained significantly associated with overall survival after
adjusting for amplified MYCN, stage 4 versus stages 1, 2, 3,
and 4s, and age at diagnosis ≥1.5 years. Of note, two of the
MYCN/c-MYC target gene clusters (clusters 168 and 140,
both from subgroup I showing a higher responsiveness to c-
MYC than to MYCN in SH-EPMYCN) revealed the strongest
association with overall survival of all 504 clusters after
adjusting for co-variables (Table 2). Figure 4 shows the asso-
ciation with overall survival for each gene from cluster 168
with and without adjustment for co-variables. Most of the
genes within this cluster, such as AHCY, ARD1A, CDK4,
HSPD1, PHB, RUVBL1, and TRAP1, remained associated
with overall survival after adjustment for co-variables. A less
significant association with overall survival was observed for
clusters with MYCN/c-MYC repressed genes: clusters 454,
482, 484, and 486 were associated with poor overall survival
without adjustment for co-variables in the Global test (p <
0.001, adjusted for multiple testing), but they showed no sig-
nificant association with poor overall survival when adjusting
for the co-variables amplified MYCN, stage 4 versus stages 1,
2, 3, and 4s, and age at diagnosis ≥1.5 years. We also asked
whether direct MYCN/c-MYC target genes as defined by our
analyses are represented in previously published gene expres-
sion-based classifiers that distinguish low-risk from high-risk
neuroblastomas independent of other risk markers. Gene
lists from these studies hardly overlapped, making interpre-
tation difficult. The overlap with our MYCN/c-MYC target
gene list was defined by using the gene names as common
identifiers. Indeed, different genes defined by our study as
direct MYCN/c-MYC target genes were represented in the
gene expression classifier gene lists: from the 44 genes over-
Table 1
MYCN/c-MYC target genes overexpressed in stage 4s-NA compared to localized-NA tumors (classes 1 and 2)
Probe Gene name Class BMU Group MYCN/c-MYC-fold change* c-MYC target DB† Validated by ChIP‡
A_24_P311604 C4orf28 1 195 I 1.38 +
A_23_P102420 CCT4 1 168 I 1.31 +
A_23_P5551 NCL 1 308 II 1.69 Up +
A_23_P44836 NT5DC2 1 140 I 1.40 +
A_32_P139196 C13ORF25V_1 2 308 II 3.83 ND
A_24_P133488 CDCA4 2 140 I 1.45 +
A_23_P137143 DKC1 2 308 II 1.93 Up +
A_23_P216396 EXOSC2 2 308 II 1.83 +
A_23_P78892 FBL 2 195 I 1.93 Up +
A_24_P228796 GAGE7B 2 195 I 1.27 ND
A_23_P41025 GNL3 2 308 II 1.80 Up ND
A_32_P8120 GNL3 2 308 II 1.81 Up ND
A_23_P398460 HK2 2 280 II 1.71 Up +
Hs172673.9 Hs172673.9 2 168 I 1.73 +
A_23_P502750 MDM2 2 336 II 1.19 ChIP +
A_23_P92261 MGC2408 2 280 II 2.14 +
A_23_P50897 MKI67IP 2 280 II 1.97 Up +
A_23_P214037 NPM1 2 140 I 1.61 Up +
A_23_P57709 PCOLCE2 2 308 II 2.40 +
A_24_P34632 PTMA 2 308 II 2.21 Up +
A_23_P126825 SLC16A1 2 195 I 1.22 +
A_23_P126291 SNRPE 2 336 II 1.49 +
A_23_P117068 SNRPF 2 336 II 1.44 +
A_23_P31536 SSBP1 2 336 II 1.24 +
A_23_P26810 TP53 2 140 I 1.44 Up +
*Fold change expression in SH-EPMYCN cells after MYCN induction. †c-MYC target gene database entry [25]: Up, upregulated; ChIP, validated by ChIP. 
‡Validation of MYCN/c-MYC binding using ChIP in this study (Additional data files 5-7). BMU, best matching unit; ND, not determined.Genome Biology 2008, 9:R150
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markers described by Schramm et al. [28], we identified 10
genes directly regulated by MYCN/c-MYC (DDX21, SCL25A3,
EIFA4A2, NME1, NME2, TKT, LDHA, LDHB, HSPD1,
HSPCB); from the 20 genes overexpressed in high-risk neu-
roblastomas independent of other markers described by
Ohira et al. [29], we identified 5 genes directly regulated by
MYCN/c-MYC (EEF1G, AHCY, TP53, ENO1, TKT); and from
the 66 genes overexpressed in high-risk neuroblastomas
independent of other markers described by Oberthuer et al.
[24], we identified 7 genes directly regulated by MYCN/c-
MYC (PRDX4, MRPL3, SNRPE, FBL, LOC200916, PAICS,
AHCY; Figure 5). Together, these results show that MYCN/c-
MYC activity as determined by the expression status of a sub-
set of MYCN/c-MYC target genes is significantly associated
with poor overall survival independent of other established
markers and is a consistent element of gene expression-based
neuroblastoma risk classification systems.
Discussion
In this study, we analyzed MYCN and c-MYC activity as
reflected by the expression levels of a core set of direct
MYCN/c-MYC targets in neuroblastoma subtypes. As
expected, the highest expression levels of MYCN/c-MYC tar-
gets were observed in MYCN amplified tumors. However, we
found that besides MYCN amplified tumors, subtypes of
MYCN single-copy tumors, namely stage 4-NA and, to a lesser
extent, stage 4s-NA, also showed increased MYCN/c-MYC
target gene activation compared to localized-NA tumors. In
general, low MYCN mRNA and protein levels are found in
most stage 4-NA tumors [14-16], which does not explain the
high mRNA levels of MYCN/c-MYC target genes in this sub-
Expression of MYCN/c-MYC target genes in neuroblastoma subtypesFigure 3
Expression of MYCN/c-MYC target genes in neuroblastoma subtypes. Differential expression was analyzed for each of the genes (n = 154) in MYCN 
amplified (AMP), stage 4s-NA and stage 4-NA tumors using localized-NA (stage 1/2/3) tumors as reference in pair-wise comparisons (Mann-Whitney test, 
cut-off p < 0.05, black). We grouped each of these 154 genes into one of four classes based on their relative expression in clinically relevant neuroblastoma 
subtypes. These classes were, compared to localized-NA tumors: overexpressed in MYCN amplified and in stage 4s-NA tumors (class 1; CCT4 and NCL); 
overexpressed in MYCN amplified, stage 4-NA and stage 4s-NA tumors (class 2; TP53 and FBL); overexpressed in MYCN amplified tumors (class 3; 
MTHFD2 and EEF1E1); and overexpressed in MYCN amplified and stage 4-NA tumors (class 4; AHCY and MRPL3).
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c-MYC expression levels in stage 4-NA and stage 4s-NA
tumors. From experiments in neuroblastoma cell lines, it is
known that MYCN and c-MYC control their expression via
autoregulatory loops and via repressing each other at defined
promoter sites [20]. Neuroblastoma cell lines with high
expression of MYCN as a result of amplification lack c-MYC
expression. Whenever MYCN and c-MYC are co-expressed in
neuroblastoma cell lines, c-MYC expression predominates.
Together, this suggests that increased activity of c-MYC
represses MYCN in a substantial number of stage 4-NA
tumors. In contrast, an inverse regulation, namely the repres-
sion of c-MYC by MYCN, is found in MYCN amplified and, to
a lesser extent, in stage 4s-NA tumors. It is important to note
that localized-NA tumors also express MYCN as well as c-
MYC and it is likely that they are active because these tumors
frequently show high tumor cell proliferation indices [14].
Nevertheless, in localized-NA tumors, we did not observe that
one MYC transcription factor dominates over the other, such
as in the other neuroblastoma subtypes.
Table 2
Association of MYCN/c-MYC target gene clusters with overall survival in primary neuroblastomas (n = 251)
Cluster Number of genes Rank OS* p-value OS† Rank OS with CV* p-value OS with CV†
168 (I) 19 3 <0.0001 1 0.0004
140 (I) 38 4 <0.0001 2 0.0006
195 (I) 21 31 <0.0001 12 0.0060
308 (II) 33 18 <0.0001 26 0.0161
280 (II) 32 29 <0.0001 37 0.0232
336 (II) 26 51 <0.0001 45 0.0280
*Rank of all 504 clusters tested for association with overall survival (OS) using the Global test without and with adjustment for co-variables (CV; 
amplified MYCN, stages 1, 2, 3, 4s versus 4, age at diagnosis ≥1.5 years). †p-value from Global test adjusted for multiple testing. In the Cluster column, 
I or II gives the cluster group as defined by the SOM analysis using SH-EPMYCN cells.
Association of cluster 168 genes with overall survivalFigure 4
Association of cluster 168 genes with overall survival. The two gene plots illustrate the influence on overall survival of each gene from cluster 168. The 
gene plot gives the influence on overall survival without (left) and with (right) adjustment for the variables genomic MYCN status, age at diagnosis (≥1.5 
years), and disease stage (stages 1, 2, 3, 4s versus stage 4). The gene plot shows a bar and a reference line for each gene tested. In a survival model, the 
expected height is zero under the null hypothesis that the gene is not associated with the clinical outcome (= reference line). Marks in the bars indicate by 
how many standard deviations the bar exceeds the reference line. The bars are colored to indicate a negative (red) association of a gene's expression with 
overall survival. In addition, the boxplot class is given for each gene.
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Representation of MYCN/c-MYC target genes in a gene expression-based neuroblastoma risk stratification system. Two-way hierarchical cluster analysis 
using 144 oligonucleotide probes from the gene expression-based classifier and the 251 patients from the entire cohort. Clinical characteristics (outcome, 
white = no event, gray = relapse/progression, black = death due to neuroblastoma; genomic MYCN status, white = NA, black = amplified; chromosome 1p 
status, white = normal, black = 1p deleted, gray = not available; chromosome 11q status, white = normal, black = 11q deleted, gray = not available; age at 
diagnosis, white <1.5 years, black ≥1.5 years; disease stage, white = stage 1, 2, gray = stage 3, yellow = stage 4s, black = stage 4) are added to the heatmap 
of gene expression. The gene expression cluster with direct MYCN/c-MYC target genes is highlighted. The Rank Classifier column gives the classifier rank 
found by the Prediction Analysis for Microarrays algorithm and a complete 10-times-repeated 10-fold cross validation. The Cluster column gives the 
results from the SOM analysis using gene expression profiles from SH-EPMYCN cells. The MYCN/c-MYC regulated column gives the fold changes after 
MYCN induction. The Ebox column gives the position of a canonical E-box in the promoter. The c-MYC TGDB column gives the entries in the public c-
MYC target gene database. *UP, upregulated.
251 patients
Rank classifier Symbol Cluster Ebox MYCN/c-MYC-regulated   c-MYC TGDB
130 VRK1 447 2 up *UP
108 FLJ10151 40 2.4 up
137 HIST1H1C 482 down/up
3 SLC25A5 383 1.8 up
90 PRDX4 221 346 1.6 up *UP
58 HSPC163 247 down/up
139 MRPL3 336 81 2.2 up
57 SNRPE 336 1.8 up
107 ZNF525 25 1.7 up
105 RPL36A 1 1.4 up *UP
110 FBL 223/195 -4 2.6 up *UP
100 BX119435 466 5.6 up
129 NOLA1 307 284 1.5 up *UP
4 GMPS 445 1.8 up
95 LOC200916 364 2.5 up
1 PAICS 364 (-283/18/617/685) 2.2 up *UP
5 AHCY 196 1.6 up *UP
13 AHCY 168 2.2 up *UP
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activation gradually increases from stage 4s-NA through
stage 4-NA to MYCN amplified tumors. High expression of a
large number of MYCN/c-MYC target genes was found in
stage 4-NA and MYCN amplified tumors, but not in stage 4s-
NA tumors, which is probably involved in the divergent clini-
cal outcome of these subtypes. This also suggests that MYCN
in stage 4s tumors is a weaker transactivator than c-MYC in
stage 4-NA tumors. Whether this effect is due to the cellular
context in which they are expressed and/or due to different
functions of the two MYC proteins in neuroblastoma cells is
unclear. In favor of a cellular context factor, we observed that
promoter constructs from the PTMA gene, which is highly
expressed in stage 4s NA and MYCN amplified tumors,
showed a strong activation in N-type but not S-type neurob-
lastoma cell lines despite similar MYCN protein levels
(unpublished data). In favor of different functions of the two
MYC proteins, our analyses in SH-EPMYCN cells suggest that a
large number of MYCN/c-MYC target genes (subgroup I
genes) are less responsive to MYCN than to c-MYC. Another
unsolved question is which molecular mechanisms induce
elevated MYCN activity in stage 4s-NA tumors or elevated c-
MYC activity in stage 4-NA tumors. Candidate pathways
involved in differential regulation of MYC proteins are the
Sonic hedgehog pathway (Shh) for MYCN activation [30] and
the Wnt/beta-catenin pathway for c-MYC activation [31,32].
However, we observed that c-MYC mRNA levels are not
significantly higher in stage 4-NA than in localized-NA
tumors. This suggests that molecular mechanisms that
increase c-MYC protein abundance/stability or simply c-MYC
activity are involved in MYCN/c-MYC target gene activation
in stage 4 tumors.
Our data are in line with a model where stage 4s-NA tumors
exhibit a moderate MYCN function gain compared to local-
ized-NA tumors. Both subtypes usually have favorable out-
come. Most localized-NA tumors are cured by surgery alone
or even regress spontaneously. Stage 4s-NA tumors fre-
quently regress spontaneously but regression can also be
induced by a 'mild' chemotherapy. We found that stage 4s-NA
tumors express, on average, the highest MYCN mRNA levels
of all non-amplified tumors [14]. From the experimentally
defined direct MYCN target genes, only a restricted set of 25
genes, including CCT4, FBL, MDM2, NCL, NPM1, PTMA, and
TP53, was overexpressed in stage 4s-NA compared to local-
ized-NA tumors, indicating that elevated MYCN in stage 4s-
NA tumors only partially activates its downstream target
genes. On the one hand, this suggests that moderate MYCN
function gain in stage 4s-NA tumors is involved in the meta-
static phenotype. On the other hand, moderate MYCN func-
tion gain in this subtype is still compatible with, or might even
favor, spontaneous regression. From the list of MYCN target
genes overexpressed in stage 4s-NA tumors, TP53 as a pro-
apoptotic gene, and MDM2, coding for the direct inhibitor of
p53 and mediating pro-tumorigenic activities, are strong can-
didates to be involved in the unique phenotype of stage 4s-NA
tumors. However, it is important to note that TP53 and
MDM2 are co-expressed at higher levels also in stage 4-NA
and MYCN amplified tumors. Both subtypes initially respond
to therapy, but rapidly acquire resistance and frequently
show progression/relapse, suggesting that additional condi-
tions activating MDM2 and/or suppressing TP53 functions
are acquired. In line with this, alterations disrupting the p14-
MDM2-p53 pathway, such as MDM2 amplification, p14
methylation/deletion, and TP53 mutations are found in neu-
roblastoma cell lines that were established from relapsed
patients [33]. In this context, it remains to be shown whether
small compounds that selectively inhibit MDM2, such as nut-
lin-3, and that induce proliferation arrest and apoptosis in
neuroblastoma cell lines [34,35] represent a new therapeutic
option for high-risk neuroblastomas.
Conclusions
High expression of a defined subset of direct MYCN/c-MYC
target genes turned out to be a robust marker for poor overall
survival independent of the established markers, amplified
MYCN, disease stage (stage 4 versus stages 1, 2, 3, and 4s) and
age at diagnosis (≥1.5 years). Recently, several gene expres-
sion-based neuroblastoma risk stratification systems have
been developed that predict outcome more accurately than
established risk markers [24,28,29]. Unfortunately, the clas-
sifier gene lists emerging from these studies hardly overlap,
which has been ascribed to the different composition of the
investigated cohorts and the different high-throughput gene
expression platforms used. Our data show that markers of
increased MYCN/c-MYC activity are consistently represented
in these classifier gene lists, indicating that a gene expression-
based classifier that reflects MYCN/c-MYC function should
make an attractive tool for neuroblastoma classification and
risk prediction.
Materials and methods
Patients
All patients from this study (n = 251) were enrolled in the Ger-
man Neuroblastoma Trials NB90-NB2004 with informed
consent and diagnosed between 1989 and 2004 (patient char-
acteristics are in Additional data files 2 and 12). Tumor sam-
ples were collected prior to any cytoreductive treatment. The
only criterion for patient selection was availability of suffi-
cient amounts of tumor material. Tumor specimens were
checked for at least 60% tumor content.
Neuroblastoma sample preparation and gene 
expression analysis
Gene expression profiles from the tumors were generated as
dye-flipped dual-color replicates using customized 11K oligo-
nucleotide microarrays as previously described [24]. The 11K
Agilent microarray was constructed in our laboratory based
on extensive neuroblastoma transcriptome information from
different whole-genome analyses from primary tumors andGenome Biology 2008, 9:R150
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transcriptome analysis of MYCN amplified versus not ampli-
fied tumors as well as of neuroblastoma cell lines with varia-
ble/conditional MYCN/c-MYC expression that allowed the
enrichment with MYCN/c-MYC-regulated genes [14,24]
(unpublished data). The reference for each tumor RNA was
an RNA pool of 100 neuroblastoma tumor samples. Data nor-
malization and quality control is described in Additional data
file 2. All raw and normalized microarray data are available at
the ArrayExpress database (Accession: E-TABM-38) [36].
Neuroblastoma cell line experiments and SOM analysis
The SH-EPMYCN cell line, previously also denoted as TET21N
[23], expressing a MYCN transgene under the control of a tet-
racycline-repressible element was used to generate gene
expression profiles from different time points after MYCN
induction showing variable MYCN and c-MYC levels. RNA
isolation from SH-EPMYCN cells was performed as previously
described [14]. Gene expression profiles were generated as
dye-flipped dual-color replicates using the same customized
11K oligonucleotide microarray platform used for the tumor
samples. The reference for RNA from SH-EPMYCN cells after
MYCN induction was RNA from SH-EPMYCN cells cultured in
parallel that lack MYCN expression. Gene expression profiles
from SH-EPMYCN cells with variable MYCN and c-MYC levels
were taken for a SOM analysis (Additional data file 2). Protein
expression was assessed by immunoblotting using 50 μg of
total cell lysates from the cell line experiments as previously
described [37]. Blots were probed with antibodies directed
against MYCN (SantaCruz, sc-53993, Santa Cruz, CA, USA)
and c-MYC (SantaCruz, sc-764, Santa Cruz, CA, USA).
ChIP, ChIP-chip and protein analysis
Chromatin immunoprecipitation was performed as described
previously [38,39] using 10 μg of MYCN (SantaCruz, sc-
53993), c-MYC (SantaCruz, sc-764) [40,41] and normal
mouse IgG (SantaCruz, sc-2025) antibodies and Dynabeads
ProteinG (Invitrogen, Carlsbad, CA, USA). Eluted and puri-
fied MYCN-ChIP-DNA (1 μl) of IMR5/75 and SH-EPMYCN was
used as a template in PCR reactions running for 35 cycles. The
primer sequences are given in Additional data file 8. In addi-
tion, ChIP-DNA templates from SH-EPMYCN, SH-EP, Kelly,
IMR5/75, SJNB-12 and SY5Y cells using MYCN and c-MYC
antibodies were amplified for DNA microarray analysis (Agi-
lent Human Promoter ChIP-chip Set 244K) using the WGA
(Sigma-Aldrich, St. Louis, MO, USA) method [42]. DNA labe-
ling, array hybridization and measurement were performed
according to Agilent mammalian ChIP-chip protocols. For
the visualization of ChIP-chip results, the cureos package
v0.2 for R was used (available upon request). The in silico
promoter analysis for the identification of putative MYC
binding sites (canonical and non-canonical E-boxes) is
described in Additional data file 2.
Differential gene expression and survival analysis
Differential gene expression of MYCN/c-MYC and their tar-
get genes in neuroblastoma tumors was evaluated for stage
4s-NA, stage 4-NA and MYCN amplified using localized-NA
tumors (stages 1, 2, 3) as reference using Goeman's Global
test and the Wilcoxon rank sum test. A result was judged as
'statistically significant' at a p-value of 0.05 or smaller. Differ-
ential expression of MYCN was evaluated in two partially
overlapping cohorts, one measured by quantitative PCR [14]
and the other by oligo microarray (the overlap was 101
patients). To test the association of MYCN in vitro clusters
with overall survival (death due to neuroblastoma disease),
Goeman's Global test was used [27]. To evaluate the influence
of gene expression on outcome independent of established
markers, the Global test was adjusted for the following co-
variables: genomic MYCN status, stage of the disease (stage 4
versus stages 1, 2, 3, and 4s), and age at diagnosis (≥1.5 years
versus <1.5 years). Because of multiple testing of probably
dependent gene clusters, p-values were adjusted according to
Benjamini and Yekutieli [43] to control the false discovery
rate of 5%.
Abbreviations
ChIP, PCR-based chromatin immunoprecipitation; ChIP-
chip, array-based chromatin immunoprecipitation; NA, non-
amplified; SOM, self-organizing map.
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Additional data files
The following additional data are available. Additional data
file 1 is a figure showing a Cluster map of genetic programs
regulated by conditional expression of c-MYC and MYCN pro-
teins in SH-EPMYCN cells. Additional data file 2 is a document
describing in more detail the methods and materials.
Additional data files 3 and 4 are sets of figures showing ChIP-
chip results of MYCN/c-MYC target genes in the Kelly and SJ-
NB12 cell lines. Additional data files 5, 6 and 7 are tables list-
ing MYCN/c-MYC target genes overexpressed in stage 4s-NA,
stage 4-NA and MYCN amplified tumors, respectively, com-
pared to localized-NA tumors. Additional data file 8 is a tableGenome Biology 2008, 9:R150
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Additional data files 9, 10 and 11 are figures showing the asso-
ciation of MYCN/c-MYC induced genes with neuroblastoma
subtypes using the Global test. Additional data file 12 is a
table providing patient data.
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